TOKYO, May 7, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved ...

TOKYO, June 29, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today the submission of a supplemental New Drug Application (sNDA) to ...

Studies comparing propiverine hydrochloride with newer antimuscarinic agents such as solifenacin succinate for the treatment of overactive bladder (OAB) in Japanese patients have not been performed.

ANTIMUSCARINICS remain the treatment of choice for OVERACTIVE BLADDER SYNDROME (OABS). A range of agents and new, extended-release formulations are currently available, each with different efficacy ...

Astellas Pharma Inc. announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of mirabegron in combination with the muscarinic ...

Nov. 23, 2004 — The U.S. Food and Drug Administration (FDA) has approved solifenacin succinate for the treatment of overactive bladder, erlotinib as second-line therapy for locally advanced or ...

As we’re rapidly approaching the middle of the year, it’s a great time to look ahead at where we’re going and the Solifenacin Succinate market Trends we’re likely to see more of in 2020. This report ...

The FDA has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 2 years of age and older.

Do not use if you have ever had an allergic reaction to SOLIFENACIN VIATRIS or any of the ingredients listed at the end of the CMI. There are a number of circumstances in which a person should not use ...

NORTHBROOK, Ill., May 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) ...

Shares of pharma major Glenmark Pharma rose as much as 2.5 percent intraday Thursday as it has received tentative USFDA nod for Solifenacin Succinate tablets. "Glenmark Pharmaceuticals Inc., USA has ...